申请人:Merck Sharp & Dohme Ltd.
公开号:US06608062B1
公开(公告)日:2003-08-19
A class of substituted 1,2,4-triazolo[4,3-]pyridazine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position, a substituted alkoxy moiety at the 6-position, and an optionally substituted bicycloalkyl ring system at the 7-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
一类取代的1,2,4-三唑并[4,3-]吡嗪衍生物,其在3位具有可选取代的环烷基、苯基或杂环芳基取代基,在6位具有取代的烷氧基,且在7位具有可选取代的双环烷基环系统,是选择性的GABAA受体配体,特别是具有高亲和力的α2和/或α3亚单位,因此对于治疗和/或预防中枢神经系统疾病,包括焦虑和惊厥,具有益处。